CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Adult Autologous Mesenchymal Bone Marrow Cellbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02165904
NCT02165904Phase 1Completed
CompareCT.gov

Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in Patients Suffering Incomplete Spinal Cord Injury (SCI)

Puerta de Hierro University Hospital·interventional·Posted Jun 18, 2014·Updated Jul 19, 2019

In Brief

A Phase 1 clinical trial evaluating Adult Autologous Mesenchymal Bone Marrow Cell for Spinal Cord Injury. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The study goes on 24 months, with recruiting, treatment and follow period for all patients. The first day for each patient will be the first cellular administration. 3 doses will be administrated every 3 months from first dose. When the clinical trial finishes, it will be done a completed check of all obtained parameters.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injury
CountriesSpain
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 18, 2014
Enrollment StartMay 1, 2014
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.0 years ago

Interventions

Adult Autologous Mesenchymal Bone Marrow Cellbiological

Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.